加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.8601
−US$0.1299 · -13.12%
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
前收盘价
US$0.8601
−US$0.1299 · -13.12%
盘后
US$0.8678
+US$0.0077 · +0.90%
10月12日 19:31 ET
盘中时间采用ET。市场数据可能有所延迟。
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$0.8601
52周区间
当前US$0.8601
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
43
合理估值
情绪
54
多空交织
风险
67
高风险
动量
27
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
日内区间
当前US$0.8601
52周区间
当前US$0.8601
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 32万 USD | — | — | — | — |
| 销货成本 | — | — | — | 12万 USD | 10.6万 USD |
| 毛利 | 32万 USD | — | — | −12万 USD | −10.6万 USD |
| 研究与开发 | 660.1万 USD | 609.6万 USD | 710.3万 USD | 693万 USD | 1419.6万 USD |
| 销售、一般及管理费用 | 632.4万 USD | 1144.2万 USD | 1002.6万 USD | 996.2万 USD | 1236万 USD |
| 营业费用 | 1292.5万 USD | 2724.1万 USD | 1712.9万 USD | 3446.3万 USD | 2655.6万 USD |
| 利息收入 | 80.1万 USD | 53.3万 USD | 2.2万 USD | 3万 USD | — |
| 利息支出 | 18.5万 USD | 65.3万 USD | 49.8万 USD | 22.3万 USD | 64万 USD |
| 折旧和摊销 | −1.3万 USD | 9000 USD | 3.7万 USD | 6万 USD | 10.6万 USD |
| 营业利润 | −1260.5万 USD | −2724.1万 USD | −1712.9万 USD | −3446.3万 USD | −2655.6万 USD |
| 净利润 | −1123.1万 USD | −2451.5万 USD | −1190.1万 USD | −1605.8万 USD | −2664.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2024年9月11日 | 1:30 | — | — |
股票拆分 | 2024年4月9日 | 1:20 | — | — |
股票拆分 | 2023年6月29日 | 1:40 | — | — |
股票拆分 | 2023年3月27日 | 1:35 | — | — |
已生效 2024年9月11日
1:30
已生效 2024年4月9日
1:20
已生效 2023年6月29日
1:40
已生效 2023年3月27日
1:35
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
